

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加 科 思 藥 業 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

**JACOBIO'S KRAS G12C AND SHP2 COMBINATION THERAPY PUBLISHED IN
THE LANCET RESPIRATORY MEDICINE**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, the Phase I/IIa clinical study results of the Company’s self-developed KRAS G12C inhibitor glecirasib in combination with the SHP2 inhibitor JAB-3312 (sitnepatib) have been published in The Lancet Respiratory Medicine, a top-tier medical journal with an impact factor of 32.8. This marks the first time that comprehensive clinical data of an all-oral KRAS G12C + SHP2 inhibitor combination have appeared in this prestigious journal.

The open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 previously untreated patients. The results showed that the combination achieved a 71% objective response rate (ORR) and 12.2 months median progression-free survival (mPFS) in the first-line population, outperforming many other first-line KRAS G12C treatment regimens. Compared with the current first-line standard of care (immunotherapy plus chemotherapy), this chemotherapy-free alternative regimen has demonstrated strong competitiveness.

Currently, the Phase III clinical trial of KRAS G12C inhibitor in combination with SHP2 inhibitor has been initiated in China, this trial will directly compare this combination regimen with the current standard of care in first-line patients, advancing this dual oral combination toward potentially becoming the first SHP2-containing combination therapy to gain approval globally.

ABOUT JACOBIO

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that glecirasib (JAB-21822) and sitnepatib (JAB-3312) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiong WANG
Chairman

Hong Kong, December 1, 2025

As at the date of this announcement, the Board comprises Dr. Yinxiong WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.